Unintended water mediated cocrystal formation in carbamazepine and aspirin tablets

Molecular Pharmaceutics

Volumn 8, Issue 3, 2011, Pages 982-989

  Arora, Kapildev K ^a   Tayade, Nitin G ^a   Suryanarayanan, Raj ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cocrystal; crystal growth; dibasic calcium phosphate dihydrate; excipients; hydrates; phase transformations; X ray diffractometry

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM PHOSPHATE DIBASIC; CARBAMAZEPINE; NICOTINAMIDE; WATER;

ARTICLE; CRYSTALLIZATION; DRUG STRUCTURE; PRIORITY JOURNAL; TABLET FORMULATION; X RAY DIFFRACTION;

ASPIRIN; CARBAMAZEPINE; CRYSTALLIZATION; TABLETS; WATER;

EID: 79958294605     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200043u     Document Type: Article

References (42)

1. Wang, J.; Davidovich, M.; Desai, D.; Bu, D.; Hussain, M.; Morris, K. Solid-State Interactions of a Drug Substance and Excipients and Their Impact on Tablet Dissolution: A Thermal-Mechanical Facilitated Process-Induced Transformation or PIT J. Pharm. Sci. 2010, 99, 3849-3862
2. Tantry, J. S.; Tank, J.; Suryanarayanan, R. Processing-Induced Phase Transitions of Theophylline-Implications on the Dissolution of Theophylline Tablets J. Pharm. Sci. 2007, 9, 1434-1444 (Pubitemid 46797500)
3. Hendriksen, B. A.; Preston, M. A.; York, P. Processing effects on crystallinity of cephalexin: characterization by vacuum microbalance Int. J. Pharm. 1995, 118, 1-10
4. Govindarajan, R.; Suryanarayanan, R. Processing-Induced Phase Tranformations and Their Implications on Pharmaceutical Product Quality. In Polymorphism: In the pharmaceutical industry; Hilfiker, R., Ed.; Wiley-VCH: Weinheim, Germany, 2006; pp 333-364.
5. Wöhler, F. Untersuchungen über des Chinons Annalen 1844, 51, 153
6. Friščić, T.; Jones, W. Benefits of cocrystallisation in pharmaceutical materials science: an update J. Pharm. Pharmacol. 2010, 62, 1547-1559
7. Arora, K. K.; Zaworotko, M. J. Pharmaceutical co-crystals: A new opportunity in pharmaceutical science for a long-known but little studied class of compounds. In Polymorphism in Pharmaceutical Solids, 2 nd ed.; Brittain, H. G., Ed.; Informa Healthcare: London, 2009; pp 282-317.
8. Schultheiss, N.; Newman, A. Pharmaceutical Cocrystals and Their Physicochemical Properties Cryst. Growth Des. 2009, 9, 2950-2967
9. Shan, N.; Zaworotko, M. J. The role of cocrystals in pharmaceutical science Drug Discovery Today 2008, 13, 440-446
10. Almarsson, Ö.; Zaworotko, M. J. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chem. Commun. 2004, 1889-1896 (Pubitemid 39335992)
11. Jung, M.-S.; Kim, J.-S.; Kim, M.-S.; Alhalaweh, A.; Cho, W.; Hwang, S.-J.; Velaga, S. P. Bioavailability of indomethacin-saccharin cocrystals J. Pharm. Pharmacol. 2010, 62, 1560-1568
12. Stanton, M. K.; Kelly, R. C.; Colletti, A.; Kiang, Y.-H.; Langley, M.; Munson, E. J.; Peterson, M. L.; Roberts, J.; Wells, M. Improved Pharmacokinetics of AMG 517 Through Co-Crystallization Part 1: Comparison of Two Acids With Corresponding Amide Co-crystals J. Pharm. Sci. 2010, 99, 3769-3778
13. Cheney, M. L.; Shan, N.; Healey, E. R.; Hanna, M.; Wojtas, L.; Zaworotko, M.; Sava, V.; Song, S.; Sanchez-Ramos, J. R. Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine Cryst. Growth Des. 2010, 10, 394-405 and references 17-19 therein
14. Kibbe, A. H., Ed. Handbook of Pharmaceutical Excipients, 3 rd ed.; American Pharmaceutical Association & Pharmaceutical Press: Washington, DC, and London, U.K., 2000.
15. Zhang, G. G. Z.; Law, D.; Schmitt, E. A.; Qiu, Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms Adv. Drug Delivery Rev. 2004, 56, 371-390 (Pubitemid 38202329)
16. Guerrieri, P. P.; Smith, D. T.; Taylor, L. S. Phase Behavior of Ranitidine HCl in the Presence of Degradants and Atmospheric Moisture-Impact on Chemical Stability Langmuir 2008, 24, 3850-3856 (Pubitemid 351568983)
17. Bak, A.; Gore, A.; Yanez, E.; Stanton, M.; Tufekcic, S.; Syed, R.; Akrami, A.; Rose, M.; Surapaneni, S.; Bostick, T.; King, A.; Neervannan, S.; Ostovic, D.; Koparkar, A. The Co-Crystal Approach to Improve the Exposure of a Water-Insoluble Compound: AMG 517 Sorbic Acid Co-Crystal Characterization and Pharmacokinetics J. Pharm. Sci. 2008, 97, 3942-3956
18. Stanton, M. K.; Bak, A. Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals Cryst. Growth Des. 2008, 8, 3856-3862
19. Khalil, S. N.; Vije, H. N.; Kee, S. S.; Farag, A.; Hanna, E.; Chuang, A. Z. A paediatric trial comparing midazolam/Syrpalta mixture with premixed midazolam syrup (Roche) Paediatr. Anaesth. 2003, 13, 205-209 (Pubitemid 36384824)
20. Bettini, R.; Pezzarossa, C.; Giordano, F.; Caira, M. R. Crystal Structure of Midazolam saccharinate Anal. Sci. 2007, 23, x143-x144
21. Puschner, B.; Poppenga, R. H.; Lowenstine, L. J.; Filligenzi, M. S.; Pesavento, P. A. Assessment of melamine and cyanuric acid toxicity in cats J. Vet. Diagn. Invest. 2007, 19, 616-624 (Pubitemid 351202170)
22. Ranganathan, A.; Pedireddi, V. R.; Rao, C. N. R. Hydrothermal Synthesis of Organic Channel Structures: 1:1 Hydrogen-Bonded Adducts of Melamine with Cyanuric and Trithiocyanuric Acids J. Am. Chem. Soc. 1999, 121, 1752-1753 (Pubitemid 29124535)
23. Khankari, R. K.; Grant, D. J. W. Pharmaceutical hydrates Thermochim. Acta 1995, 248, 61-79
24. Morris, K. R. Structural aspects of hydrates and solvates. In Polymorphism in Pharmaceutical solids; Britain, H. G., Ed.; Marcel Dekker, Inc.: New York, 1999; pp 126-180.
25. Giron, D.; Goldbronn, C.; Mutz, M.; Pfeffer, S.; Piechon, P.; Schwab, P. Solid State Characeterization of Pharmaceutical Hydrates J. Therm. Anal. Calorim. 2002, 68, 453-465 (Pubitemid 34614446)
26. Griesser, U. J. The importance of solvates. In Polymorphism: In the pharmaceutical industry; Hilfiker, R., Ed.; Wiley-VCH: Weinheim, Germany, 2006; pp 211-233.
27. Raula, J.; Thielmann, F.; Kansikas, J.; Hietala, S.; Annala, M.; Seppälä, J.; Lähde, A.; Kauppinen, E. I. Investigations on the Humidity-Induced Transformations of Salbutamol Sulphate Particles Coated with L-Leucine Pharm. Res. 2008, 25, 2250-2261
28. Chowhan, Z. T. The effect of low- and high-humidity ageing on the hardness, disintegration time and dissolution rate of dibasic calcium phosphate-based tablets J. Pharm. Pharmacol. 1980, 32, 10-14 (Pubitemid 10184745)
29. Mirza, S.; Heinämäki, J.; Miroshnyk, I.; Rantanen, J.; Christiansen, L.; Karjalainen, M.; Yliruusi, J. Understanding Processing-Induced Phase Transformations in Erythromycin-PEG 6000 Solid Dispersions J. Pharm. Sci. 2006, 95, 1723-1732 (Pubitemid 44229579)
30. Miyazaki, T.; Sivaprakasam, K.; Tantry, J. S.; Suryanarayanan, R. Physical Characterization of Dibasic Calcium Phosphate Dihydrate and Anhydrate J. Pharm. Sci. 2009, 98, 905-916
31. Kaushal, A. M.; Vangala, V. R.; Suryanarayanan, R. Unusual Effect of Water Vapor Pressure on Dehydration of Dibasic Calcium Phosphate Dihydrate J. Pharm. Sci. 2010, 100, 1456-1466
32. Landín, M.; Perez-Marcos, B.; Casalderrey, M.; Martínez-Pacheco, R.; Gómez-Amoza, J. L.; Souto, C.; Concheiro, A.; Rowe, R. C. Chemical stability of acetylsalicylic acid in tablets prepared with different commercial brands of dicalcium phosphate dihydrate Int. J. Pharm. 1994, 107, 247-249 (Pubitemid 24182112)
33. Landín, M.; Casalderrey, M.; Martínez-Pacheco, R.; Gómez-Amoza, J. L.; Souto, C.; Concheiro, A.; Rowe, R. C. Chemical stability of acetylsalicylic acid in tablets prepared with different particle size fractions of a commercial brand of dicalcium phosphate dihydrate Int. J. Pharm. 1995, 123, 143-144
34. Fleischman, S. G.; Kuduva, S. S.; McMahon, J. A.; Moulton, B.; Walsh, R. D. B.; Rodríguez-Hornedo, N.; Zaworotko, M. J. Crystal Engineering of the Composition of Pharmaceutical Phases: Multiple-Component Crystalline Solids Involving Carbamazepine Cryst. Growth Des. 2003, 3, 909-919 (Pubitemid 37474229)
35. Allen, F. H.; Kennard, O. 3D search and research using the Cambridge Structural Database Chem. Des. Autom. News 1993, 8, 31-37
36. Allen, F. H. The Cambridge Structural Database: A Quarter of a Million Crystal Structures and Rising Acta Crystallogr. 2002, B58, 380-388 (Pubitemid 135702674)
37. Chieng, N.; Hubert, M.; Saville, D.; Rades, T.; Aaltonen, J. Formation Kinetics and Stability of Carbamazepine-Nicotinamide Cocrystals Prepared by Mechanical Activation Cryst. Growth Des. 2009, 9, 2377-2386
38. Maheshwari, C.; Jayasankar, A.; Khan, N. A.; Amidon, G. E.; Rodríguez-Hornedo, N. Factors that influence the spontaneous formation of pharmaceutical cocrystals by simply mixing solid reactants CrystEngComm 2009, 11, 493-500
39. Jayasankar, A.; Good, D. J.; Rodríguez-Hornedo, N. Mechanisms by Which Moisture Generates Cocrystals Mol. Pharmaceutics 2007, 4, 360-372 (Pubitemid 46983953)
40. Vishweshwar, P.; McMahon, J. A.; Oliveira, M.; Peterson, M. L.; Zaworotko, M. J. The Predictably Elusive Form II of Aspirin J. Am. Chem. Soc. 2005, 127, 16802-16803 (Pubitemid 41772837)
41. Childs, S. L.; Rodríguez-Hornedo, N.; Reddy, L. S.; Jayasankar, A.; Maheshwari, C.; McCausland, L.; Shipplett, R.; Stahly, B. C. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine CrystEngComm 2008, 10, 856-864
42. The United States Pharmacopeia 34/The National Formulary 29; United States Pharmacopeial Convention: Rockville, MD, 2010.